INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th
MWN-AI** Summary
INmune Bio Inc. (NASDAQ: INMB) is set to report its financial results for the first quarter of 2025 on May 8th, at 4:30 PM EDT. The Boca Raton-based clinical-stage biotechnology firm specializes in harnessing the innate immune system to treat various diseases, particularly focusing on neuroinflammation associated with Alzheimer's Disease (AD). This upcoming conference call will serve as a platform for the company to disclose its financial outcomes for the quarter ending March 31, 2025, along with a broader corporate update.
INmune Bio is advancing three primary product platforms aimed at chronic inflammation and cancer. Firstly, its Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform is exploring treatments for Mild Alzheimer’s Disease and treatment-resistant depression through candidates like XPro™. Secondly, the Natural Killer Cell Priming Platform includes INKmune®, which is currently in trials to enhance NK cell response in metastatic castration-resistant prostate cancer patients. Lastly, the company’s CORDStrom™ program leverages human umbilical cord-derived stem cells and has recently completed a trial in recessive dystrophic epidermolysis bullosa.
Potential investors and stakeholders are encouraged to join the conference call by dialing in approximately 5-10 minutes prior, and details are available through a live audio webcast. INmune Bio remains dedicated to developing innovative therapies, but engages investors with caution, acknowledging the inherent risks and uncertainties in its clinical trial progress and regulatory approvals. As the company gears up for this pivotal conference call, it aims to illuminate its ongoing research and future strategies, which could significantly influence its market standing and investor interest. For more information about INmune Bio, visit their website at www.inmunebio.com.
MWN-AI** Analysis
As we approach INmune Bio Inc.'s (NASDAQ: INMB) first quarter 2025 financial results to be reported on May 8, 2025, investors should carefully consider the company’s strategic positioning and the implications of its clinical progress. INmune Bio operates within a promising niche, focusing on neuroinflammation and chronic diseases linked to immune dysfunction, particularly Alzheimer's Disease (AD) — a growing concern amid an aging population.
In analyzing INmune Bio, it is pivotal to understand its three primary product platforms, particularly the Dominant-Negative Tumor Necrosis Factor (DN-TNF) and its potential applications in AD. The company’s focus on infiltrating the central nervous system and mitigating neuroinflammation positions it well within a competitive market that is increasingly receptive to innovative therapeutic approaches. Investors will be keen to hear updates on progress with its clinical trials for conditions like Mild Cognitive Impairment and treatment-resistant depression, as positive outcomes could significantly enhance the company's valuation and market sentiment.
However, it’s essential to remain cognizant of the risks associated with biopharmaceutical investments, particularly the uncertainties surrounding FDA approvals and the timeframes involved in clinical reviews. Financial sustainability is another critical focus; INmune Bio must ensure it secures adequate funding to support its research and operational expenditures, especially given the capital-intensive nature of drug development.
Overall, while the market potential is significant and the therapeutic pipeline intriguing, potential investors should proceed with caution. Watch for key indicators during the upcoming conference call, specifically any data on trial advancements and funding announcements, which will elucidate INmune Bio's capacity to deliver on its ambitious objectives. Continual monitoring of regulatory landscapes and competitive dynamics in the immunology domain will also be crucial moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Boca Raton, Florida, May 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s Disease (AD), today announced that it will host a conference call on Thursday, May 8 th , 2025 at 4:30pm EDT to discuss results for its quarter ended March 31, 2025 and to provide a corporate update.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching the operator.
Date: May 8 th , 2025
Time: 4:30 PM Eastern Time
Participant Dial-in: 1-800-267-6316 Participant Dial-in (international): +1-203-518-9783
Conference ID: INMUNE
A live audio webcast of the call can be accessed by clicking here or using this link:
https://viavid.webcasts.com/starthere.jsp?ei=1712673&tp_key=b29f89f7f9
A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through May 22nd, 2025 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering pin no. 11158539.
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune® developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is currently in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom™, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. INmune Bio’s product platforms utilize a precision medicine approach for diseases driven by chronic inflammation and cancer. To learn more, please visit www.inmunebio.com .
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss, CFO
(561) 710-0512
info@inmunebio.com
Investor Contact:
Daniel Carlson, Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
FAQ**
How does INmune Bio Inc. (NASDAQ: INMB) plan to advance its clinical trials for treatments addressing Alzheimer's Disease and other conditions through its DN-TNF product platform?
What are the key milestones INmune Bio Inc. (NASDAQ: INMB) expects to achieve in the upcoming quarter, specifically regarding its product candidates currently in clinical trials?
Can you provide insights into the funding status of INmune Bio Inc. (NASDAQ: INMB) and its strategy for securing the necessary resources for ongoing research and development activities?
How does INmune Bio Inc. (NASDAQ: INMB) assess potential risks and uncertainties that could impact the timelines for FDA approval of its clinical candidates in the near future?
**MWN-AI FAQ is based on asking OpenAI questions about INmune Bio Inc. (NASDAQ: INMB).
NASDAQ: INMB
INMB Trading
-5.44% G/L:
$1.565 Last:
646,918 Volume:
$1.66 Open:
